2022 (v1)
Publication
No description
Uploaded on: February 14, 2024
-
-
2023 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2017 (v1)Publication
Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis...
Uploaded on: April 14, 2023 -
2025 (v1)Publication
: Direct-acting antiviral (DAA) therapy is associated with a significant reduction in hepatocellular carcinoma (HCC) incidence among patients with cirrhosis, but data are conflicting about the risk of recurrence following DAA therapy. DAA-PASS was a prospective, pragmatic, observational study designed to estimate the risk of HCC recurrence...
Uploaded on: April 19, 2025